Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Short Interest Update

Sol-Gel Technologies Ltd. (NASDAQ:SLGL) was the target of a large decline in short interest in September. As of September 15th, there was short interest totalling 97,000 shares, a decline of 33.9% from the August 31st total of 146,700 shares. Approximately 1.0% of the company’s stock are short sold. Based on an average daily volume of 389,800 shares, the days-to-cover ratio is currently 0.2 days.

Sol-Gel Technologies Stock Performance

SLGL traded down $0.03 during midday trading on Friday, reaching $0.68. 27,425 shares of the company were exchanged, compared to its average volume of 155,747. The company has a market cap of $18.94 million, a price-to-earnings ratio of -0.82 and a beta of 1.57. Sol-Gel Technologies has a one year low of $0.33 and a one year high of $1.89. The company’s fifty day moving average price is $0.57 and its 200 day moving average price is $0.77.

Sol-Gel Technologies (NASDAQ:SLGL) last announced its quarterly earnings results on Friday, August 16th. The company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.27. Sol-Gel Technologies had a negative return on equity of 39.95% and a negative net margin of 227.40%. The business had revenue of $5.43 million during the quarter, compared to the consensus estimate of $1.06 million. As a group, sell-side analysts anticipate that Sol-Gel Technologies will post -0.57 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Raymond James lowered shares of Sol-Gel Technologies from a “strong-buy” rating to an “outperform” rating and dropped their price objective for the company from $6.00 to $4.00 in a research note on Monday, August 19th.

About Sol-Gel Technologies

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc, develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.